Explore this article's sources with AI
Follow PeptideMethods on Google
What PT-141 actually costs in the UK
Zero official UK PT-141 prices were found. Here is why a specials quote, a US Vyleesi price and a research-vendor listing are different numbers.
Why we wrote this. UK readers need an official-price absence finding that excludes seller quotes and keeps PT-141, bremelanotide and Vyleesi product identities separate.
In this article (9 sections)
- PT-141, bremelanotide and Vyleesi require separate price checks
- What the UK product record showed
- Why there is no ordinary NHS price
- The specials route is quoted case by case
- Why a US Vyleesi price is not a UK price
- Why grey-market prices are excluded
- Clinic packages may contain several different costs
- How to check for a future official price
- The current cost answer is an official-price absence
There is no official UK pharmacy price for PT-141 that we can responsibly quote. On 8 November 2026, exact searches of the MHRA product-information service returned no results for bremelanotide or Vyleesi.[1] The current EMA medicine workbook also contained no match for PT-141, PT 141, bremelanotide or Vyleesi.[2] No identified UK finished product means there is no licensed pack, routine NHS reimbursement amount or standard patient charge to report.
The accurate result is zero official UK prices found, not a price of zero pounds. A licensed importer or pharmacy might produce a patient-specific quote under the unlicensed-medicine framework. That would be the cost of one proposed supply, not a national tariff. Research-vendor listings are excluded because they do not establish an equivalent regulated product or lawful UK supply.
PT-141, bremelanotide and Vyleesi require separate price checks
PubChem lists PT-141 as a name associated with bremelanotide.[3] DailyMed identifies Vyleesi as a US prescription autoinjector containing 1.75 mg bremelanotide.[4] The name relationship is useful when searching records, but it does not make a powder vial the same finished product as Vyleesi.
A comparable medicine price needs a defined manufacturer, strength, dosage form, pack size and regulatory route. Vyleesi supplies those facts for the US product. A research listing may use the same molecule name while describing another formulation and supply chain. Its displayed amount cannot be transferred to the US autoinjector or treated as a UK pack price.
What the UK product record showed
The MHRA Products service says UK-authorised medicines carry licence identifiers such as PL, PLGB or PLNI numbers. Exact searches for bremelanotide and Vyleesi displayed no results on 8 November 2026.[1] That is a dated search finding under those names. It does not reveal confidential applications or decide whether a differently named product could appear later.
EMA's downloadable workbook is a separate central European inventory. We searched the underlying workbook content for PT-141, PT 141, bremelanotide and Vyleesi and found zero matches.[2] The EMA result supports absence from that central dataset under the names checked. It does not replace the national MHRA search.
Why there is no ordinary NHS price
Regulation 46 of the Human Medicines Regulations 2012 sets the ordinary rule that an unauthorised medicinal product may not be sold or supplied unless an exemption applies.[5] With no matching authorised UK product identified, there is no licensed PT-141 or Vyleesi pack that can enter routine prescribing, pharmacy dispensing and reimbursement under those names.
This is why searches for an NHS cost do not lead to a defensible number. NHS charges and reimbursement rules operate on identifiable medicines and services. There is no pack, licence number, NHS list price or standard prescription item here to calculate. It would be misleading to borrow eligibility criteria or patient charges from another medicine simply because both may be discussed in sexual-health care.
The absence of a routine price does not prove that every patient-specific request has been refused. It means no public product-level input was found for a national calculation. Private insurance also does not create a UK marketing authorisation or tariff. Any insurer decision would concern the exact policy, clinical request and proposed supply.
The specials route is quoted case by case
MHRA guidance describes specials as unlicensed medicines manufactured or imported for the treatment of an individual patient after an order from an authorised prescriber.[6] The broader import guidance requires the appropriate manufacturer or wholesale licence, prior notification and no MHRA objection before an unlicensed medicine is imported.[7]
That route does not publish one PT-141 price. A lawful proposal would need to identify the foreign finished product, licensed importer, pharmacy, prescriber and clinical need. Its quote could include the source product, transport, regulatory handling, dispensing and professional fees. Those components vary by case, so one quote cannot be presented as the UK price.
Vyleesi's US approval does not guarantee that a UK special would be ordered, accepted or funded. The MHRA guidance establishes a mechanism, not an entitlement for this molecule. We found no public UK bremelanotide specials tariff. Inventing an estimate would conceal the missing product and route information rather than answer the question.
Why a US Vyleesi price is not a UK price
A US cash amount belongs to the American authorisation, distribution and insurance system. Converting dollars to pounds produces only a currency conversion. It leaves out whether a UK prescriber would request the product, whether a licensed importer could source it, the pack supplied, handling charges and any patient-specific funding decision.
The same problem applies to overseas pharmacy advertisements. Even if a listing is for genuine Vyleesi, the advertised US amount does not establish a lawful delivered cost in the UK. If it is instead a vial labelled PT-141, the product is different before exchange rates are even considered. Price comparison starts with identity, not a shared molecule name.
Why grey-market prices are excluded
Research sellers advertise vials labelled PT-141 in pounds, but those figures are not official medicine prices. Listings may describe different claimed quantities, formulations, batch testing and shipping terms. More fundamentally, a seller page cannot prove the vial's identity, concentration, sterility or regulated release. Averaging the offers would create a precise-looking number without a stable product denominator.
A monthly estimate would add an unsupported regimen. It would require assumptions about quantity and frequency, then apply them to products that may not be equivalent. The Vyleesi label is evidence about one regulated US autoinjector and its approved population. It is not a dosing or cost template for research vials. This page does not create a schedule to manufacture a monthly price.
Clinic packages may contain several different costs
A private clinic package can combine consultation, tests, follow-up and dispensing with a medicine charge. Those are real services, but the package total is not automatically the price of bremelanotide. Ask for an itemised quote and the exact medicine, manufacturer, pack and pharmacy. If the proposal names only PT-141, there is not enough information to compare it with Vyleesi or a future UK-authorised product.
Separate the medicine charge from professional and logistics fees. Confirm whether the product is licensed in the source country, who imports it and whether the supply is a notified special. A low package figure can reflect an unidentified research vial. A high figure can include extensive clinical services. Neither becomes an official UK pack price merely because it appears on an invoice.
How to check for a future official price
Repeat the MHRA Products searches for bremelanotide and Vyleesi, then inspect the exact licence and pack if a result appears. Check the current EMA inventory separately. A new authorisation would still not establish NHS funding on its own, so verify any formulary or reimbursement claim against the named NHS body and ask a registered pharmacy for the current patient charge.
For related context, use the UK regulation hub and the PT-141 evidence overview. These pages do not turn seller quotes into official prices or guarantee patient-specific supply.
The current cost answer is an official-price absence
As of 8 November 2026, no matching MHRA product was identified for bremelanotide or Vyleesi, and no matching central EMA record was found under the identity terms checked. The defensible answer is zero official UK prices found. A patient-specific specials quote may differ, but vendor listings, US conversions and invented monthly totals cannot fill the public-record gap.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Regulatory disclaimer: This page reflects our understanding of the regulatory status and official price records as of 8 November 2026. Regulations and prices change. Verify with the official regulator and a registered pharmacy before making any decision. PeptideMethods.com is not a law firm and does not provide legal advice.
Frequently asked
How much does PT-141 cost in the UK?
Zero official UK prices were found on 8 November 2026. That means no matching licensed pack or national price was identified, not that the medicine costs zero pounds.
Is PT-141 available on the NHS?
No matching MHRA-authorised product was identified, so there is no routine licensed pack, NHS reimbursement amount or standard patient charge to quote under PT-141, bremelanotide or Vyleesi.
Can a UK pharmacy quote for Vyleesi as a special?
A patient-specific unlicensed-medicine route exists under prescriber responsibility through licensed participants. The framework does not guarantee that Vyleesi will be supplied or funded, and any quote would be case-specific rather than a national tariff.
Why are online PT-141 prices excluded?
Research-vendor listings are not official UK medicine prices and may not describe equivalent or regulator-verified products. A displayed amount does not prove identity, concentration, sterility or lawful supply.
Are PT-141 and Vyleesi the same product?
PT-141 is a name associated with bremelanotide. Vyleesi is a specific US prescription autoinjector. A powder vial is not automatically that finished product.
Sources
- [1]MHRA Products: exact bremelanotide search returned no results on 8 November 2026Tier 1 · primary↩
- [2]European Medicines Agency: downloadable medicine dataTier 1 · primary↩
- [3]NIH PubChem: Bremelanotide compound record and PT-141 synonymTier 1 · primary↩
- [4]DailyMed: Vyleesi (bremelanotide) US prescribing informationTier 1 · primary↩
- [5]The Human Medicines Regulations 2012, regulation 46Tier 1 · primary↩
- [6]MHRA: Supply unlicensed medicinal products (specials)Tier 1 · primary↩
- [7]MHRA: Import a human medicineTier 1 · primary↩
No revisions yet. First published .